Clinical Trial Update: MSC for Treatment of Interstitial Lung Disease After Allo-HSCT [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating mesenchymal stem cells for interstitial lung disease after allogeneic hematopoietic stem cell transplantation, includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans
• Interstitial Lung Disease

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Lung Diseases, Interstitial, Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Status: UNKNOWN